Refine
Has Fulltext
- no (16)
Document Type
- Article (16) (remove)
Language
- English (16)
Is part of the Bibliography
- yes (16)
Keywords
- Monoclonal antibody (3)
- Monoclonal antibodies (2)
- hybridoma technology (2)
- monoclonal antibody (2)
- 3D (1)
- Antibody generation (1)
- Antiphospholipid antibody (1)
- Antiphospholipid syndrome (1)
- Assay calibration (1)
- Assay systems (1)
- Autoimmune diagnostics (1)
- B cell activation (1)
- B lymphocytes (1)
- Beta2-glycoprotein I (1)
- Bgl2p (1)
- Camelid antibodies (1)
- Camelid single domain antibodies (1)
- Candida (1)
- Chronic obstructive pulmonary disease (COPD) (1)
- Cross reactivity (1)
- Detection (1)
- Diagnostics (1)
- Disease monitoring (1)
- Epitope mapping (1)
- Flow cytometry (1)
- GP2 isoform alpha (1)
- Geltrex (1)
- Hapten (1)
- Heavy-chain only antibodies (1)
- Hybridoma technology (1)
- Immunology (1)
- Immunosensor (1)
- In vitro immunization (1)
- In vivo biotinylation (1)
- Issue 119 (1)
- Leukotriene B4 (1)
- Line immunoassay (1)
- Microbeads (1)
- Multiplexed assays (1)
- Omicron (1)
- Peptides (1)
- Phospholipid binding proteins (1)
- SARS-CoV-2 (1)
- Secondary antibodies (1)
- Vaccination (1)
- VideoScan technology (1)
- acute pancreatitis (1)
- antibody (1)
- antibody producing cell selection (1)
- antigen (1)
- camelid antibody (1)
- camelid heavy-chain-only antibodies (1)
- cell culture (1)
- chronic pancreatitis (1)
- epitope prediction (1)
- glycoprotein GP2 (1)
- heavy-chain-only antibody (1)
- hybridoma (1)
- immunconjugate (1)
- in vitro immunization (1)
- miRNA (1)
- monoclonal antibodies (1)
- myeloma cells (1)
- nanobodies (1)
- neutralization (1)
- novel biomarkers (1)
- nucleic acids (1)
- pancreatic neoplasms (1)
- severe acute pancreatitis (1)
- single domain antibodies (1)
- zymogen granule membrane glycoprotein GP2 (1)
Institute
The discovery that certain diseases have specific miRNA signatures which correspond to disease progression opens a new biomarker category. The detection of these small non-coding RNAs is performed routinely using body fluids or tissues with real-time PCR, next-generation sequencing, or amplification-based miRNA assays. Antibody-based detection systems allow an easy onset handling compared to PCR or sequencing and can be considered as alternative methods to support miRNA diagnostic in the future. In this study, we describe the generation of a camelid heavy-chain-only antibody specifically recognizing miRNAs to establish an antibody-based detection method. The generation of nucleic acid-specific binders is a challenge. We selected camelid binders via phage display, expressed them as VHH as well as full-length antibodies, and characterized the binding to several miRNAs from a signature specific for dilated cardiomyopathy. The described workflow can be used to create miRNA-specific binders and establish antibody-based detection methods to provide an additional way to analyze disease-specific miRNA signatures.